Antibody-drug conjugates(ADCs)are commonly heterogeneous and require extensive assessment of exposure-efficacy and exposure-safety relationships in preclinical and clinical studies.In this study,we report the generati...Antibody-drug conjugates(ADCs)are commonly heterogeneous and require extensive assessment of exposure-efficacy and exposure-safety relationships in preclinical and clinical studies.In this study,we report the generation of a monoclonal antibody against monomethyl auristatin E(MMAE)and the development,validation,and application of sensitive and high-throughput enzyme-linked immunosorbent assays(ELISA)to measure the concentrations of MMAE-conjugated ADCs and total antibodies(tAb,antibodies in ADC plus unconjugated antibodies)in cynomolgus monkey sera.These assays were successfully applied to in vitro plasma stability and pharmacokinetic(PK)studies of SMADC001,an MMAE-conjugated ADC against trophoblast cell surface antigen 2(TROP-2).The plasma stability of SMADC001 was better than that of similar ADCs coupled with PEG4-Val-Cit,Lys(m-dPEG24)-Cit,and Val-Cit linkers.The developed ELISA methods for the calibration standards of ADC and tAb revealed a correlation between serum concentrations and the OD450 values,with R2 at 1.000,and the dynamic range was 0.3-35.0 ng/mL and 0.2-22.0 ng/mL,respectively;the intra-and inter-assay accuracy bias%ranged from -12.2% to -5.2%,precision ranged from -12.4% to -1.4%,and the relative standard deviation(RSD)was less than 6.6% and 8.7%,respectively.The total error was less than 20.4%.The development and validation steps of these two assays met the acceptance criteria for all addressed validation parameters,which suggested that these can be applied to quantify MMAE-conjugated ADCs,as well as in PK studies.Furthermore,these assays can be easily adopted for development of other similar immunoassays.展开更多
Friction occurs in our daily lives, and statistics have shown that it consumes approximately 1/3 of the primary energy. In addition,mechanical interface friction significantly impacts the efficiency,noise, accuracy, c...Friction occurs in our daily lives, and statistics have shown that it consumes approximately 1/3 of the primary energy. In addition,mechanical interface friction significantly impacts the efficiency,noise, accuracy, corrosion, reliability, and operational lifespans of equipment. Several studies have revealed various methods for reducing the coefficient of friction (COF) to the superlubricity state(COF <0.01) through efficient lubrication technology.展开更多
Effective drugs with broad spectrum safety profile to all people are highly expected to combat COVID-19 caused by SARS-CoV-2.Here we report that nelfinavir,an FDA approved drug for the treatment of HIV infection,is ef...Effective drugs with broad spectrum safety profile to all people are highly expected to combat COVID-19 caused by SARS-CoV-2.Here we report that nelfinavir,an FDA approved drug for the treatment of HIV infection,is effective against SARS-CoV-2 and COVID-19.Preincubation of nelfinavir could inhibit the activity of the main protease of the SARS-CoV-2(IC50=8.26μM),while its antiviral activity in Vero E6 cells against a clinical isolate of SARS-CoV-2 was determined to be 2.93μM(EC50).In comparison with vehicle-treated animals,rhesus macaque prophylactically treated with nelfinavir had significantly lower temperature and significantly reduced virus loads in the nasal and anal swabs of the animals.At necropsy,nelfinavir-treated animals had a significant reduction of the viral replication in the lungs by nearly three orders of magnitude.A prospective clinic study with 37 enrolled treatment-naive patients at Shanghai Public Health Clinical Center,which were randomized(1:1)to nelfinavir and control groups,showed that the nelfinavir treatment could shorten the duration of viral shedding by 5.5 days(9.0 vs.14.5 days,P=0.055)and the duration of fever time by 3.8 days(2.8 vs.6.6 days,P=0.014)in mild/moderate COVID-19 patients.The antiviral efficiency and clinical benefits in rhesus macaque model and in COVID-19 patients,together with its well-established good safety profile in almost all ages and during pregnancy,indicated that nelfinavir is a highly promising medication with the potential of preventative effect for the treatment of COVID-19.展开更多
Dear Editor,SARS-coronavirus-2(SARS-CoV-2)Omicron variant(B.1.1.529)is of great concern to the world due to its multiple mutations that may have an impact on transmissibility and immune evasion.1 Compared to the wild ...Dear Editor,SARS-coronavirus-2(SARS-CoV-2)Omicron variant(B.1.1.529)is of great concern to the world due to its multiple mutations that may have an impact on transmissibility and immune evasion.1 Compared to the wild type(WT),Omicron carries as many as 30 single point mutations,3 deletion mutation and one insertion mutation on its spike protein.Strikingly,there are 15 mutations observed in the Omicron receptor-binding domain(RBD),10 of which are in the receptor-binding motif(RBM)that human angiotensin-converting enzyme 2(ACE2)and most monoclonal antibodies(mAbs)interact directly with.As a comparison,the currently dominant variant Delta(B.1.617.2)has only 2 mutations(L452R and T478K)in its RBM and additional K417N and E484K mutations sometimes.Therefore,Omicron variant may significantly impact the binding affinity to ACE2 and effectiveness of currently available mAbs.Consequently,Omicron mutant has aroused wide concern,many countries have taken measures on entry restrictions to prevent its rapid spread.However,the transmissibility and immune evasion risk of Omicron have not been properly evaluated.展开更多
Glycosite-specific antibody-drug conjugatess(gsADCs), harnessing Asn297 N-glycan of IgG Fc as the conjugation site for drug payloads, usually require multi-step glycoengineering with two or more enzymes, which limits ...Glycosite-specific antibody-drug conjugatess(gsADCs), harnessing Asn297 N-glycan of IgG Fc as the conjugation site for drug payloads, usually require multi-step glycoengineering with two or more enzymes, which limits the substrate diversification and complicates the preparation process.Herein, we report a series of novel disaccharide-based substrates, which reprogram the IgG glycoengineering to one-step synthesis of gsADCs, catalyzed by an endo-N-acetylglucosaminidase(ENGase) of Endo-S2. IgG glycoengineering via ENGases usually has two steps: deglycosylation by wild-type(WT) ENGases and transglycosylation by mutated ENGases. But in the current method, we have found that disaccharide LacNAc oxazoline can be efficiently assembled onto IgG by WT Endo-S2 without hydrolysis of the product, which enables the one-step glycoengineering directly from native antibodies.Further studies on substrate specificity revealed that this approach has excellent tolerance on various modification of 6-Gal motif of LacNAc. Within 1 h, one-step synthesis of gsADC was achieved using the LacNAc-toxin substrates including structures free of bioorthogonal groups. These gsADCs demonstrated good homogeneity, buffer stability, in vitro and in vivo anti-tumor activity. This work presents a novel strategy using LacNAc-based substrates to reprogram the multi-step IgG glycoengineering to a one-step manner for highly efficient synthesis of gsADCs.展开更多
基金supported by the China National Major Scientific and Technological Special Project for“Significant New Drugs Innovation and Development”(Grant No.:2019ZX09732002-006)the National New Drug Creation Program of China(Grant No.:2018ZX09201017-004)+5 种基金the Strategic Priority Research Program of the Chinese Academy of Sciences(Grant Nos.:XDA12020223,XDA12020330,XDA12020360,and XDA12050305)the National Natural Science Foundation of China(Grant Nos.:81872785 and 81673347)the Science and Technology Planning Projects of Department of Science and Technology Province(Grant No.:20190202)Shanghai Municipal Commission of Science and Technology of China(Grant Nos.:17431904400,19YF1457400,and 21S11904500)Institutes for Drug Discovery and Development,the Chinese Academy of Sciences(Grant Nos.:CASIMM0120202007 and CASIMM0120202008)Major Scientific and Technological Special Project of Zhongshan City(Grant Nos.:191022172638719 and 210205143867019).
文摘Antibody-drug conjugates(ADCs)are commonly heterogeneous and require extensive assessment of exposure-efficacy and exposure-safety relationships in preclinical and clinical studies.In this study,we report the generation of a monoclonal antibody against monomethyl auristatin E(MMAE)and the development,validation,and application of sensitive and high-throughput enzyme-linked immunosorbent assays(ELISA)to measure the concentrations of MMAE-conjugated ADCs and total antibodies(tAb,antibodies in ADC plus unconjugated antibodies)in cynomolgus monkey sera.These assays were successfully applied to in vitro plasma stability and pharmacokinetic(PK)studies of SMADC001,an MMAE-conjugated ADC against trophoblast cell surface antigen 2(TROP-2).The plasma stability of SMADC001 was better than that of similar ADCs coupled with PEG4-Val-Cit,Lys(m-dPEG24)-Cit,and Val-Cit linkers.The developed ELISA methods for the calibration standards of ADC and tAb revealed a correlation between serum concentrations and the OD450 values,with R2 at 1.000,and the dynamic range was 0.3-35.0 ng/mL and 0.2-22.0 ng/mL,respectively;the intra-and inter-assay accuracy bias%ranged from -12.2% to -5.2%,precision ranged from -12.4% to -1.4%,and the relative standard deviation(RSD)was less than 6.6% and 8.7%,respectively.The total error was less than 20.4%.The development and validation steps of these two assays met the acceptance criteria for all addressed validation parameters,which suggested that these can be applied to quantify MMAE-conjugated ADCs,as well as in PK studies.Furthermore,these assays can be easily adopted for development of other similar immunoassays.
基金supported by the National Natural Science Foundation of China (52250112, 62104020, and 52275197)Beijing Natural Science Foundation (3232019)。
文摘Friction occurs in our daily lives, and statistics have shown that it consumes approximately 1/3 of the primary energy. In addition,mechanical interface friction significantly impacts the efficiency,noise, accuracy, corrosion, reliability, and operational lifespans of equipment. Several studies have revealed various methods for reducing the coefficient of friction (COF) to the superlubricity state(COF <0.01) through efficient lubrication technology.
基金supported by the Natural Science Foundation of Shanghai (21ZR1475600)Science and Technology Commission of Shanghai Municipality (20431900100)+4 种基金Shanghai Science and Technology Committee (19430750100)National Key R&D Program of China (2016YFA0502301 and 2021YFC2301204)Drug development for the newly emerging viral infectious diseases (SIMM010107)Fundamental Research Funds for the Central Universities (2022ZFJH003)Zhejiang Provincial Key Research&Development Program of China (2021C03043 and No.2021C03039).
文摘Effective drugs with broad spectrum safety profile to all people are highly expected to combat COVID-19 caused by SARS-CoV-2.Here we report that nelfinavir,an FDA approved drug for the treatment of HIV infection,is effective against SARS-CoV-2 and COVID-19.Preincubation of nelfinavir could inhibit the activity of the main protease of the SARS-CoV-2(IC50=8.26μM),while its antiviral activity in Vero E6 cells against a clinical isolate of SARS-CoV-2 was determined to be 2.93μM(EC50).In comparison with vehicle-treated animals,rhesus macaque prophylactically treated with nelfinavir had significantly lower temperature and significantly reduced virus loads in the nasal and anal swabs of the animals.At necropsy,nelfinavir-treated animals had a significant reduction of the viral replication in the lungs by nearly three orders of magnitude.A prospective clinic study with 37 enrolled treatment-naive patients at Shanghai Public Health Clinical Center,which were randomized(1:1)to nelfinavir and control groups,showed that the nelfinavir treatment could shorten the duration of viral shedding by 5.5 days(9.0 vs.14.5 days,P=0.055)and the duration of fever time by 3.8 days(2.8 vs.6.6 days,P=0.014)in mild/moderate COVID-19 patients.The antiviral efficiency and clinical benefits in rhesus macaque model and in COVID-19 patients,together with its well-established good safety profile in almost all ages and during pregnancy,indicated that nelfinavir is a highly promising medication with the potential of preventative effect for the treatment of COVID-19.
基金This work was supported by the Natural Science Foundation of Shanghai(21ZR1475600)National Key R&D Program of China(2016YFA0502301&2017YFB0202601)+2 种基金the National Science Foundation of China(U1811462)the open fund from the State Key Laboratory of High-Performance Computing(No.201901-11)The work was partially carried out on the new generation Tianhe Supercomputer.
文摘Dear Editor,SARS-coronavirus-2(SARS-CoV-2)Omicron variant(B.1.1.529)is of great concern to the world due to its multiple mutations that may have an impact on transmissibility and immune evasion.1 Compared to the wild type(WT),Omicron carries as many as 30 single point mutations,3 deletion mutation and one insertion mutation on its spike protein.Strikingly,there are 15 mutations observed in the Omicron receptor-binding domain(RBD),10 of which are in the receptor-binding motif(RBM)that human angiotensin-converting enzyme 2(ACE2)and most monoclonal antibodies(mAbs)interact directly with.As a comparison,the currently dominant variant Delta(B.1.617.2)has only 2 mutations(L452R and T478K)in its RBM and additional K417N and E484K mutations sometimes.Therefore,Omicron variant may significantly impact the binding affinity to ACE2 and effectiveness of currently available mAbs.Consequently,Omicron mutant has aroused wide concern,many countries have taken measures on entry restrictions to prevent its rapid spread.However,the transmissibility and immune evasion risk of Omicron have not been properly evaluated.
基金supported by the National Natural Science Foundation of China(NSFC,No.,2187116 and 82003574)Shanghai Municipal Science and Technology Major Project,the Shanghai Sail Program(No.19YF1457100)the Special Research Assistant Program(Chinese Academy of Sciences,CAS),Natural Science Foundation of Shandong Province(ZR2017BC062)。
文摘Glycosite-specific antibody-drug conjugatess(gsADCs), harnessing Asn297 N-glycan of IgG Fc as the conjugation site for drug payloads, usually require multi-step glycoengineering with two or more enzymes, which limits the substrate diversification and complicates the preparation process.Herein, we report a series of novel disaccharide-based substrates, which reprogram the IgG glycoengineering to one-step synthesis of gsADCs, catalyzed by an endo-N-acetylglucosaminidase(ENGase) of Endo-S2. IgG glycoengineering via ENGases usually has two steps: deglycosylation by wild-type(WT) ENGases and transglycosylation by mutated ENGases. But in the current method, we have found that disaccharide LacNAc oxazoline can be efficiently assembled onto IgG by WT Endo-S2 without hydrolysis of the product, which enables the one-step glycoengineering directly from native antibodies.Further studies on substrate specificity revealed that this approach has excellent tolerance on various modification of 6-Gal motif of LacNAc. Within 1 h, one-step synthesis of gsADC was achieved using the LacNAc-toxin substrates including structures free of bioorthogonal groups. These gsADCs demonstrated good homogeneity, buffer stability, in vitro and in vivo anti-tumor activity. This work presents a novel strategy using LacNAc-based substrates to reprogram the multi-step IgG glycoengineering to a one-step manner for highly efficient synthesis of gsADCs.